Glioma Patients' voices heard: radiotherapy vs. new drug in Quality-of-Life showdown
NCT ID NCT07547163
First seen Apr 29, 2026 · Last updated Jun 16, 2026 · Updated 8 times
Summary
This study listens to patients with a slow-growing brain tumor (IDH-mutant grade 2 glioma) to understand how they feel during treatment. It compares two approaches: radiotherapy and a drug called vorasidenib, plus a group just being watched. The goal is to learn which treatment better preserves quality of life and eases anxiety, using simple questionnaires.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GLIOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fondazione IRCCS Istituto Neurologico Carlo Besta
RECRUITINGMilan, Italy
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.